Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019
in Wuhan city. This new coronavirus causes a disease that has now been named COVID-19. The
virus has subsequently spread throughout the world and was declared a pandemic by the World
Health Organisation on 11th March 2020. As of April 1, 2020, there are 874.081 numbers of
confirmed cases with 43.290 fatalities. There is no approved therapy for COVID-19 and the
current standard of care is supportive treatment.
Key markers implying a fatal outcome are acute respiratory distress syndrome (ARDS)-like
disease with pronounced dyspnea, hypoxia and radiological changes in the lung. Senicapoc
improves oxygenation and reduces fluid retention, inflammation, and bleeding in the lungs of
mice with ARDS-like disease. In cells, there is an antiviral effect of senicapoc.
Phase:
Phase 2
Details
Lead Sponsor:
University of Aarhus
Collaborators:
Aalborg University Hospital Aarhus University Hospital Hvidovre University Hospital Odense University Hospital